Ptc Therapeutics (PTCT) Operating Leases: 2019-2025
Historic Operating Leases for Ptc Therapeutics (PTCT) over the last 5 years, with Sep 2025 value amounting to $107.3 million.
- Ptc Therapeutics' Operating Leases rose 10.75% to $107.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.3 million, marking a year-over-year increase of 10.75%. This contributed to the annual value of $74.9 million for FY2024, which is 23.23% down from last year.
- Ptc Therapeutics' Operating Leases amounted to $107.3 million in Q3 2025, which was up 29.33% from $83.0 million recorded in Q2 2025.
- In the past 5 years, Ptc Therapeutics' Operating Leases ranged from a high of $146.3 million in Q2 2022 and a low of $73.6 million during Q4 2021.
- Over the past 3 years, Ptc Therapeutics' median Operating Leases value was $97.6 million (recorded in 2023), while the average stood at $99.0 million.
- Its Operating Leases has fluctuated over the past 5 years, first soared by 91.37% in 2022, then dropped by 28.80% in 2025.
- Ptc Therapeutics' Operating Leases (Quarterly) stood at $73.6 million in 2021, then soared by 37.00% to $100.9 million in 2022, then dropped by 3.21% to $97.6 million in 2023, then fell by 23.23% to $74.9 million in 2024, then increased by 10.75% to $107.3 million in 2025.
- Its Operating Leases stands at $107.3 million for Q3 2025, versus $83.0 million for Q2 2025 and $85.0 million for Q1 2025.